文献速递主动脉疾病

睡眠呼吸暂停综合征患者Stanford B型主动脉夹层腔内治疗结局

Outcomes of endovascular therapy for Stanford type B aortic dissection in patients with sleep apnea syndrome.
PubMed 文献 · J Vasc Surg · 2024-06-24

本观察性研究纳入2018年1月至2022年12月接受胸主动脉腔内修复术(TEVAR)的Stanford B型主动脉夹层(TBAD)合并睡眠呼吸暂停综合征(SAS)患者121例,按便携式睡眠呼吸监测分为轻度SAS组(MSAS,74例)和中重度SAS组(MSSAS,47例)。MSSAS组全因死亡率显著高于MSAS组(log-rank P = .027),多因素Cox回归校正后仍显著(HR 1.875,95%CI 1.238-2.586,P = .012),远端支架扩张速率也更高(P = .029)。

要点

  • MSSAS组全因死亡率显著高于MSAS组(log-rank P = .027),校正混杂后HR 1.875(95%CI 1.238-2.586,P = .012)。
  • MSSAS组远端支架扩张速率高于MSAS组(P = .029)。
  • 两组内漏、支架诱发新入口及支架移位等并发症无显著差异。

核心结论

  • MSSAS与TBAD患者TEVAR术后更高的全因死亡风险和远端支架扩张速率相关。
  • 作者认为及时积极逆转这些患者的SAS严重程度似乎是必要的。

研究设计与样本

  • 观察性研究,聚焦2018年1月至2022年12月期间接受TEVAR的TBAD合并SAS患者。
  • 根据便携式睡眠呼吸监测系统结果分为轻度SAS组(MSAS,74例)和中重度SAS组(MSSAS,47例),共纳入121例。

主要发现

  • MSSAS组年龄大于MSAS组(51.7 ± 8.3岁 vs 57.1 ± 12.8岁;P = .012)。
  • MSSAS组BMI高于MSAS组(25.7 ± 2.3 kg/m2 vs 27.0 ± 2.3 kg/m2;P = .038)。
  • 两组并发症无显著差异:内漏P = .403,支架诱发新入口P > .999,支架移位P > .999。
  • MSSAS组全因死亡率显著高于MSAS组(log-rank P = .027);马凡综合征合并MSSAS者全因死亡率也显著高于马凡综合征合并MSAS者(log-rank P = .037)。
  • 两组免于再干预率无显著差异(log-rank P = .278);MSSAS组远端支架扩张速率高于MSAS组(HR 2.5 mm/年[95%CI 2-3 mm/年] vs HR 4 mm/年[95%CI 2.0-5.5 mm/年];P = .029)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to determine the influences of varying severity of sleep apnea syndrome (SAS) on the outcomes after thoracic endovascular aorta repair (TEVAR) in patients with Stanford type B aortic dissection (TBAD). METHODS: This observational study focused on individuals with TBAD plus SAS who received TEVAR between January 2018 and December 2022. Patients were divided into groups according to the results of the portable sleep-breathing monitoring systems: mild SAS (MSAS) and moderate-to-severe SAS (MSSAS). Clinical profiles were collected and analyzed. RESULTS: A total of 121 cases with TBAD plus SAS who underwent TEVAR were enrolled in this study. Two groups were formed by stratifying these cases: MSAS (74 cases) and MSSAS (47 cases). The MSSAS cases were found to be older relative to MSAS cases (51.7 ± 8.3 years vs 57.1 ± 12.8 years; P = .012) and had a higher body mass index (BMI; 25.7 ± 2.3 kg/m2vs 27.0 ± 2.3 kg/m2; P = .038). The investigation did not find any appreciable differences between the MSAS and MSSAS groups in terms of complications (endoleak, P = .403; stent-induced new entry, P >.999; and stent displacement: P >.999). However, the MSSAS group exhibited a significantly higher overall mortality rate compared with the MSAS group (log-rank P = .027). The tendency continued when examining cases with Marfan syndrome combined with MSSAS, where the overall mortality rate was significantly greater compared with Marfan syndrome cases with MSAS (log-rank P = .037). The absence of a significant difference was noteworthy in the freedom from reintervention between the MSAS and MSSAS groups (log-rank P = .278). The overall mortality rate was significantly higher in MSSAS group even after adjusting for varying potential confounders in the multivariate cox regression analysis (hazard ratio [HR], 1.875; 95% confidence interval [CI], 1.238-2.586; P = .012). A markedly higher rate of distal stent dilation in the MSSAS group was also observed compared with the MSAS group (HR, 2.5 mm/year [95% CI, 2-3 mm/year] vs HR, 4 mm/year [95% CI, 2.0-5.5 mm/year]; P = .029). CONCLUSIONS: MSSAS is associated with a significantly higher risk of overall mortality and dilation rate of the distal stent after TEVAR for TBAD patients. Hence, aggressive efforts to reverse the severity of SAS in time in these individuals seem to be necessary.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Luo ZR, Wang ZS, Chen YX, et al. Outcomes of endovascular therapy for Stanford type B aortic dissection in patients with sleep apnea syndrome. J Vasc Surg. 2024. PMID: 38925349. doi:10.1016/j.jvs.2024.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。